Canada markets closed
  • S&P/TSX

    21,077.35
    -85.30 (-0.40%)
     
  • S&P 500

    4,701.21
    +14.46 (+0.31%)
     
  • DOW

    35,754.75
    +35.32 (+0.10%)
     
  • CAD/USD

    0.7902
    -0.0004 (-0.05%)
     
  • CRUDE OIL

    73.11
    +0.75 (+1.04%)
     
  • BTC-CAD

    62,929.35
    -1,164.92 (-1.82%)
     
  • CMC Crypto 200

    1,302.12
    -3.00 (-0.23%)
     
  • GOLD FUTURES

    1,783.10
    -2.40 (-0.13%)
     
  • RUSSELL 2000

    2,271.71
    +17.92 (+0.80%)
     
  • 10-Yr Bond

    1.5090
    +0.0290 (+1.96%)
     
  • NASDAQ futures

    16,415.00
    +22.75 (+0.14%)
     
  • VOLATILITY

    19.90
    -1.99 (-9.09%)
     
  • FTSE

    7,337.05
    -2.85 (-0.04%)
     
  • NIKKEI 225

    28,818.53
    -42.09 (-0.15%)
     
  • CAD/EUR

    0.6970
    +0.0003 (+0.04%)
     

Helix BioPharma Corp. Announces Appointment of New Director

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

RICHMOND HILL, ON / ACCESSWIRE / August 19, 2021 / Helix BioPharma Corp. (TSX:HBP) ('Helix' or the 'Company'), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Dr. Krzysztof Saczek has been appointed as a member of the Board of Directors of the Company effective immediately.

Dr. Saczek is a Paediatric Surgeon, experienced in treating solid tumors, including malignancies in children. He has trained and practiced in several prominent medical centers in North America, Europe and South Africa. His area of expertise includes gastro-intestinal oncology. Dr. Saczek's professional designations include being a member of the Saskatchewan Medical Association and the CPSS (College of Physicians and Surgeons of Saskatchewan). Currently, Dr. Saczek is the Head of Paediatric Surgery Department at the Regina General Hospital in Regina, Saskatchewan.

Prof. Majewski said: "We are excited to have Dr. Saczek join the Helix Board of Directors. Dr. Saczek brings a wealth of experience to the Company and we look forward to having the opportunity to work with him in further developing the Company's immunotherapy treatments strategy going forward."

About Helix BioPharma Corp.
Helix BioPharma Corp. is a clinical-stage biopharmaceutical company developing unique therapies in the field of immune-oncology for the prevention and treatment of cancer based on our proprietary technological platform DOS47. Helix is listed on the Toronto Stock Exchange under the symbol "HBP".

For more information, please contact:
Helix BioPharma Corp.
9120 Leslie Street, Suite 205
Richmond Hill, Ontario, L4B 3J9
Tel: 905-841-2300 x 233
Frank Michalargias, Chief Financial Officer
ir@helixbiopharma.com

Investor Relations
Alpha Bronze, LLC
Mr. Pascal Nigen
Phone: + 1 (917) 385-2160
helix@alphabronze.net

Forward-Looking Statements and Risks and Uncertainties
This news release contains forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates, statements regarding plans, goals, objectives, intentions and expectations with respect to the Company's future business, operations, research and development, including the Company's activities relating to DOS47, and other information in future periods. Forward-looking statements can further be identified by the use of forward-looking terminology such as "ongoing", "estimates", "expects", or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions "will", "may", "could", or "should" occur or be achieved, or comparable terminology referring to future events or results.

Forward-looking statements are statements about the future and are inherently uncertain, and are necessarily based upon a number of estimates and assumptions that are also uncertain. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Forward-looking statements, including financial outlooks, are intended to provide information about management's current plans and expectations regarding future operations, including without limitation, future financing requirements, and may not be appropriate for other purposes. Certain material factors, estimates or assumptions have been applied in making forward-looking statements in this news release, including, but not limited to, the safety and efficacy of L-DOS47; that sufficient financing will be obtained in a timely manner to allow the Company to continue operations and implement its clinical trials in the manner and on the timelines anticipated; the timely provision of services and supplies or other performance of contracts by third parties; future costs; the absence of any material changes in business strategy or plans; and the timely receipt of required regulatory approvals and strategic partner support.

The Company's actual results could differ materially from those anticipated in the forward-looking statements contained in this news release as a result of numerous known and unknown risks and uncertainties, including without limitation, the risk that the Company's assumptions may prove to be incorrect; the risk that additional financing may not be obtainable in a timely manner, or at all, and that clinical trials may not commence or complete within anticipated timelines or the anticipated budget or may fail; third party suppliers of necessary services or of drug product and other materials may fail to perform or be unwilling or unable to supply the Company, which could cause delay or cancellation of the Company's research and development activities; necessary regulatory approvals may not be granted or may be withdrawn; the Company may not be able to secure necessary strategic partner support; general economic conditions, intellectual property and insurance risks; changes in business strategy or plans; and other risks and uncertainties referred to elsewhere in this news release, any of which could cause actual results to vary materially from current results or the Company's anticipated future results. Certain of these risks and uncertainties, and others affecting the Company, are more fully described in the Company's annual management's discussion and analysis for the year ended July 31, 2020 under the heading "Risks and Uncertainties" and Helix's Annual Information Form, in particular under the headings "Forward-looking Statements" and "Risk Factors", and other reports filed under the Company's profile on SEDAR at www.sedar.com from time to time. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix's management on the date of this new release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.

SOURCE: Helix BioPharma Corp.



View source version on accesswire.com:
https://www.accesswire.com/660436/Helix-BioPharma-CorpAnnounces-Appointment-of-New-Director

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting